Holen Sie sich die Stockscreener-App
126.61
0.45%
-0.57
Handel nachbörslich:
126.61
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$127.18
Offen:
$126.97
24-Stunden-Volumen:
4.72M
Relative Volume:
0.82
Marktkapitalisierung:
$220.36B
Einnahmen:
$43.84B
Nettoeinkommen (Verlust:
$13.94B
KGV:
15.83
EPS:
7.9979
Netto-Cashflow:
$6.78B
1W Leistung:
-0.73%
1M Leistung:
-5.20%
6M Leistung:
-2.25%
1J Leistung:
+10.99%
1-Tages-Spanne:
$126.19
$128.45
1-Wochen-Bereich:
$125.00
$128.94
52-Wochen-Spanne:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
126.61 | 221.35B | 43.84B | 13.94B | 6.78B | 7.9979 |
|
BSX
Boston Scientific Corp
|
100.97 | 151.78B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
375.93 | 146.70B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
93.23 | 120.73B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
82.19 | 47.45B | 5.69B | 1.41B | 577.90M | 6.9828 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Eingeleitet | The Benchmark Company | Buy |
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Data supports Abbott Tendyne mitral valve replacement - MassDevice
Billionaire Israel "Izzy" Englander Has Loaded Up on This Dividend King. Should You? - The Motley Fool
Technical signs of recovery in Abbott LaboratoriesMarket Volume Summary & Target Return Focused Stock Picks - newser.com
Abbott Laboratories, facing hundreds of lawsuits over safety of formula for premature babies, notches a win in federal court - Slipcase
Abbott’s New Study on Dydrogesterone: A Potential Game-Changer for Endometriosis Pain - TipRanks
Is Abbott Laboratories (Common Stock) (ABL0) stock a buy for dividend portfoliosJuly 2025 Price Swings & Precise Buy Zone Identification - Fundação Cultural do Pará
Abbott Laboratories wins Illinois court case on NEC baby formula claims - Global Food Industry News
Using R and stats models for Abbott Laboratories forecastingWeekly Market Summary & Real-Time Volume Triggers - newser.com
What is the fair value estimate for Abbott Laboratories (ABL) stock in 2025Trade Risk Report & Smart Swing Trading Techniques - newser.com
Will a bounce in Abbott Laboratories offer an exitSwing Trade & High Conviction Investment Ideas - newser.com
Is Abbott Laboratories stock a buy in volatile marketsGap Up & Verified Stock Trade Ideas - newser.com
Abbott Laboratories (ABT) Surged Ahead of the Market in 2025 with Steady Earnings Momentum - MSN
Will Abbott Laboratories (ABL) stock maintain strong growthStop Loss & Verified Momentum Stock Watchlist - newser.com
Abbott Laboratories wins lawsuit over safety of baby formula - Chicago Tribune
Abbott Wins Third Bellwether as Judge Rules Human-Milk Alternative ‘Unfeasible’ - USA Herald
Abbott Wins Third Bellwether In Cow Milk Baby Formula MDL - Law360
Abbott wins third of four 'bellwether' infant formula lawsuits - Crain's Chicago Business
Protein Bar Market Size, Share, and Growth 2025-2035 | Abbott - openPR.com
Abbott Can't Expand Glucose Monitor Sales Ban At UPC - Law360
Abbott Laboratories (ABT): Exploring Valuation After a Recent Share Price Pullback - Yahoo Finance
Meet RFK’s Corporate Underlings - The American Prospect
Is Abbott Laboratories stock dividend growth reliableJuly 2025 Catalysts & Smart Swing Trading Alerts - newser.com
How Abbott’s Innovative Partnerships Are Shaping Its 2025 Valuation Amid 12.8% YTD Gain - simplywall.st
United States Chronic Obstructive Pulmonary Disease Market Report 2025-2033, Profiles of AstraZeneca, Pfizer, GSK, Novartis, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim, Almirall - GlobeNewswire
1 Safe-and-Steady Stock with Exciting Potential and 2 We Question - The Globe and Mail
Synlait Milk Confirms Investment Regulator's Approval for Abbott's Acquisition of North Island Assets - MarketScreener
A Look Into Abbott Laboratories Inc's Price Over Earnings - Sahm
Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock - Yahoo Finance
The 5 Most Interesting Analyst Questions From Abbott Laboratories’s Q3 Earnings Call - Yahoo Finance
How Abbott Laboratories stock compares to growth peersMarket Movement Recap & Free Weekly Watchlist of Top Performers - newser.com
Can Abbott Laboratories (Common Stock) (ABL0) stock sustain margin levelsGap Down & Entry and Exit Point Strategies - newser.com
Is Abbott Laboratories (ABL) stock cheap by valuation metricsTake Profit & Risk Adjusted Buy/Sell Alerts - newser.com
Is Abbott Laboratories showing signs of accumulationMarket Movement Recap & Expert Approved Momentum Ideas - newser.com
Volatility clustering patterns for Abbott LaboratoriesPortfolio Risk Report & Real-Time Market Trend Scan - newser.com
Walmart to sell Abbott's CGM in US 1st - Fierce Biotech
Abbott - Boston Athletic Association
Daiwa Securities Adjusts Abbott Laboratories Price Target to $136 From $134, Maintains Outperform Rating - MarketScreener
Walmart to be first US retailer to sell Abbott's continuous glucose monitor - Reuters
Walmart (WMT) Expands Health Offerings with Abbott's Lingo Gluco - GuruFocus
Functional Foods Forecast and Company Analysis Report 2025: A $678.32 Billion Market by 2033 Featuring Abbott, Amway, BASF, Cargill, Clif Ba, Danone, General Mills, Kellogg, Kerry, Nestle - Yahoo Finance
Walmart said to become first physical retailer to sell Abbott’s OTC glucose monitor, Lingo - Seeking Alpha
Walmart to be first US retailer to sell Abbott's continuous glucose monitor, Axios reports - TradingView
How to read the order book for Abbott Laboratories2025 Earnings Surprises & Trade Opportunity Analysis Reports - newser.com
Abbott Laboratories (ABT) Rated Buy as Benchmark Highlights Diagnostics Growth and Global Resilience - Insider Monkey
Bringing Biomarkers to the Bedside: The Clinical Promise of Abbott’s TBI Test - NeurologyLive
Did Mixed Segment Results and Narrowed Guidance Just Shift Abbott Laboratories' (ABT) Investment Narrative? - Yahoo Finance
Boston Scientific (BSX) Reports Q3: Everything You Need To Know Ahead Of Earnings - TradingView
Will Abbott Laboratories price bounce be sustainableTrade Entry Report & Step-by-Step Swing Trade Plans - newser.com
Why analysts recommend Abbott Laboratories (ABL) stockPortfolio Return Summary & AI Powered Trade Plan Recommendations - newser.com
Is Abbott Laboratories (ABL) stock a safe buy pre earningsTrade Exit Report & Weekly Top Gainers Trade List - Trung tâm Dự báo KTTV quốc gia
Lobbying Update: $1,128,989 of ABBOTT LABORATORIES lobbying was just disclosed - Quiver Quantitative
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.43%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):